- Technology Sony IMX 686 Vs Samsung ISOCELL Bright GW1: Battle Of 64MP Smartphone Cameras
- Movies Sargun Mehta Wishes Hubby Ravi Dubey On Their 6th Wedding Anniversary With A Sweet Message
- News Amid violence Jharkhand Assembly polls 2nd phase ended with 63.36% voters turnout
- Sports Manchester City 1-2 Manchester United: Rashford and Martial land big win for Solskjaer
- Automobiles KTM 790 Adventure Showcased At India Bike Week Ahead Of 2020 Launch
- Finance Now 5,500 Railway Stations Have Free WiFi
- Education TOEFL Go! Global: A Mobile App From ETS To Stand Out In Exam
- Travel A Brief Travel Guide For Solo Travellers To Conquer South India
Liver is one of the most vital organs. Any damage to the liver can cause serious affect on the entire body functioning. Hence, having a healthy liver is essential.
Well, if you have any liver related ailment and want to keep yourself away from further deteriorating and risk of developing liver cancer, then you need to check here for a possible preventive measure.
A new study has found that people with hepatitis B virus (HBV) who took an aspirin a day - often recommended to help prevent cardiovascular disease and had a lower risk of developing liver cancer.
Chronic hepatitis B or C, heavy alcohol use, fatty liver disease and other causes of liver injury can lead to the development of cirrhosis and hepatocellular carcinoma (HCC), a type of primary liver cancer.
The study looked at a nationwide cohort using medical records from the Taiwan National Health Insurance Research Database between 1998 and 2012.
During the study, the researchers had taken into consideration 1553 people who had used continuous daily aspirin therapy for at least three months, averaging nearly four years. They were matched by age and sex with four people who did not regularly take aspirin (totalling 6212 control subjects).
About three quarters were men and the average age was 54 years. About 5% had liver cirrhosis and under 10% were treated with nucleoside/nucleotide analogues. Pre-existing cardiovascular disease and risk factors such as diabetes and high blood pressure were more common in the aspirin group.
Following the study, it was noted that the incidence of liver cancer among people taking daily aspirin was significantly lower than the rate in the non-aspirin group. On the other hand about 3% of people in the aspirin group developed HCC over five years, this rose to about 6% in the non-aspirin group.
Aspirin therapy was associated with a 37% reduction in the risk of HCC in patients with chronic hepatitis B.
The study was recently presented at the 2017 AASLD Liver meeting held at Washington, DC.
(With Agency Inputs)